Lin28A Drives hepatic fibrosis by suppressing HMGA2/HIF-1α-Dependent ferroptosis in hepatic stellate cells
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.117900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Ankang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, PR China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Ferroptosis, Hepatic Stellate Cells, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, China International Medical Foundation, National Key Research and Development Program of China.
Abstract (Originalsprache)
Effective therapies for liver fibrosis are lacking. The RNA-binding protein Lin28A is upregulated in human cirrhotic and mouse fibrotic livers, where it localizes to activated hepatic stellate cells (HSCs). HSCs-specific overexpression of Lin28A worsened carbon tetrachloride (CCl4)-induced fibrosis in mice. In LX-2 and primary mouse HSCs, Lin28A knockdown suppressed activation and induced hallmarks of ferroptosis, including mitochondrial damage, lipid peroxidation, and glutathione depletion. Mechanistically, Lin28A repressed the maturation of let-7 microRNAs, leading to increased expression of its target, high-mobility group AT-hook 2 (HMGA2). HMGA2, alongside hypoxia-inducible factor-1α (HIF-1α), contributed to the downregulation of the ferroptosis defense proteins SLC7A11 and GPX4. Notably, the anti-fibrotic effects of the Lin28A inhibitor C1632 were dependent on ferroptosis induction, as co-treatment with ferrostatin-1 reversed its impact on HSCS activation and death. In vivo, C1632 treatment alleviated CCl4-induced liver fibrosis. These results identify Lin28A as a regulator of HSCS ferroptosis and a potential target for anti-fibrotic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, PR China.
- The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, PR China; Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, PR China; Key Laboratory of Biotherapy and Re…
- Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, PR China.
- The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, PR China; Key Laboratory of Biotherapy and Regenerative Medicine of Gansu Province, Lanzhou 730000, PR China. Electronic address: yaoj06@lzu.edu…
Förderung
- Natural Science Foundation of Sichuan Province
- China International Medical Foundation
- National Key Research and Development Program of China
- Sichuan Province Department of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Wang, A., Sun, H., Zhao, H., Xie, Y., Yan, M., Zhang, Y., Song, X., Ding, F., Chai, C., Ni, H., Yao, J., & Li, X. (2026). Lin28A Drives hepatic fibrosis by suppressing HMGA2/HIF-1α-Dependent ferroptosis in hepatic stellate cells. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117900
Vancouver
Wang A, Sun H, Zhao H, Xie Y, Yan M, Zhang Y, et al. Lin28A Drives hepatic fibrosis by suppressing HMGA2/HIF-1α-Dependent ferroptosis in hepatic stellate cells. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117900
BibTeX
@article{Wang2026,
author = {Wang, Ankang and Sun, Hongfa and Zhao, Haixia and Xie, Ye and Yan, Mengchao and Zhang, Yue and Song, Xiaojing and Ding, Fanghui and Chai, Changpeng and Ni, Haixu and Yao, Jia and Li, Xun},
title = {Lin28A Drives hepatic fibrosis by suppressing HMGA2/HIF-1α-Dependent ferroptosis in hepatic stellate cells},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.117900}
}
EUVIMED